New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases

Matteo Bauckneht, Dario Arnaldi, Flavio Nobili, Dag Aarsland, Silvia Morbelli

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The term Lewy body diseases (LBDs) refers to a subset of neurodegenerative disorders that share the accumulation of the so-called Lewy bodies (LB) including: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and PD later characterized by the occurrence of dementia (PDD). Moreover, multiple system atrophy (MSA) and idiopatic Rem Sleeping behaviour disorders (RBD) complete the group of synucleinopathies and have also common symptoms with respect to LBDs. The clinical diagnosis of LBDs can be challenging for physicians, particularly in the early stages of disease. Given the growing number of individuals affected by these neurodegenerative disorders, early and accurate diagnosis can lead to improved clinical management of patients. For this reason, information obtained from molecular imaging biomarkers is playing an increasingly important role in this framework. The present narrative review discusses both established milestones and new evidence on the use of molecular imaging tracers already part of the clinical practice as well as available evidence on new molecular imaging approaches in PD, PDD and DLB.

Original languageEnglish
Pages (from-to)3105-3130
Number of pages26
JournalCurrent Medicinal Chemistry
Volume25
Issue number26
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Molecular imaging
Lewy Body Disease
Molecular Imaging
Parkinson Disease
Neurodegenerative Diseases
Dementia
Multiple System Atrophy
Mental Disorders
Early Diagnosis
Biomarkers
Physicians

Keywords

  • lewy bodies dementia
  • molecular imaging
  • Parkinson disease
  • Parkinson disease dementia
  • positron emission tomography
  • single photon emission tomography.

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases. / Bauckneht, Matteo; Arnaldi, Dario; Nobili, Flavio; Aarsland, Dag; Morbelli, Silvia.

In: Current Medicinal Chemistry, Vol. 25, No. 26, 01.01.2018, p. 3105-3130.

Research output: Contribution to journalReview article

@article{133da3d09580476dad4a232f97cde64a,
title = "New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases",
abstract = "The term Lewy body diseases (LBDs) refers to a subset of neurodegenerative disorders that share the accumulation of the so-called Lewy bodies (LB) including: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and PD later characterized by the occurrence of dementia (PDD). Moreover, multiple system atrophy (MSA) and idiopatic Rem Sleeping behaviour disorders (RBD) complete the group of synucleinopathies and have also common symptoms with respect to LBDs. The clinical diagnosis of LBDs can be challenging for physicians, particularly in the early stages of disease. Given the growing number of individuals affected by these neurodegenerative disorders, early and accurate diagnosis can lead to improved clinical management of patients. For this reason, information obtained from molecular imaging biomarkers is playing an increasingly important role in this framework. The present narrative review discusses both established milestones and new evidence on the use of molecular imaging tracers already part of the clinical practice as well as available evidence on new molecular imaging approaches in PD, PDD and DLB.",
keywords = "lewy bodies dementia, molecular imaging, Parkinson disease, Parkinson disease dementia, positron emission tomography, single photon emission tomography.",
author = "Matteo Bauckneht and Dario Arnaldi and Flavio Nobili and Dag Aarsland and Silvia Morbelli",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/0929867324666170609080000",
language = "English",
volume = "25",
pages = "3105--3130",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "26",

}

TY - JOUR

T1 - New Tracers and New Perspectives for Molecular Imaging in Lewy Body Diseases

AU - Bauckneht, Matteo

AU - Arnaldi, Dario

AU - Nobili, Flavio

AU - Aarsland, Dag

AU - Morbelli, Silvia

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The term Lewy body diseases (LBDs) refers to a subset of neurodegenerative disorders that share the accumulation of the so-called Lewy bodies (LB) including: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and PD later characterized by the occurrence of dementia (PDD). Moreover, multiple system atrophy (MSA) and idiopatic Rem Sleeping behaviour disorders (RBD) complete the group of synucleinopathies and have also common symptoms with respect to LBDs. The clinical diagnosis of LBDs can be challenging for physicians, particularly in the early stages of disease. Given the growing number of individuals affected by these neurodegenerative disorders, early and accurate diagnosis can lead to improved clinical management of patients. For this reason, information obtained from molecular imaging biomarkers is playing an increasingly important role in this framework. The present narrative review discusses both established milestones and new evidence on the use of molecular imaging tracers already part of the clinical practice as well as available evidence on new molecular imaging approaches in PD, PDD and DLB.

AB - The term Lewy body diseases (LBDs) refers to a subset of neurodegenerative disorders that share the accumulation of the so-called Lewy bodies (LB) including: Parkinson's disease (PD), dementia with Lewy bodies (DLB), and PD later characterized by the occurrence of dementia (PDD). Moreover, multiple system atrophy (MSA) and idiopatic Rem Sleeping behaviour disorders (RBD) complete the group of synucleinopathies and have also common symptoms with respect to LBDs. The clinical diagnosis of LBDs can be challenging for physicians, particularly in the early stages of disease. Given the growing number of individuals affected by these neurodegenerative disorders, early and accurate diagnosis can lead to improved clinical management of patients. For this reason, information obtained from molecular imaging biomarkers is playing an increasingly important role in this framework. The present narrative review discusses both established milestones and new evidence on the use of molecular imaging tracers already part of the clinical practice as well as available evidence on new molecular imaging approaches in PD, PDD and DLB.

KW - lewy bodies dementia

KW - molecular imaging

KW - Parkinson disease

KW - Parkinson disease dementia

KW - positron emission tomography

KW - single photon emission tomography.

UR - http://www.scopus.com/inward/record.url?scp=85053131028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053131028&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170609080000

DO - 10.2174/0929867324666170609080000

M3 - Review article

C2 - 28595550

AN - SCOPUS:85053131028

VL - 25

SP - 3105

EP - 3130

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 26

ER -